Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults

@inproceedings{Ermer2013DoubleblindPT,
  title={Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults},
  author={James C. Ermer and Mary B. Haffey and Cynthia Richards and Kenneth C. Lasseter and Ben A Adeyi and Mary E. Corcoran and Beverly Stanton and Patrick T. Martin},
  booktitle={Neuropsychiatric disease and treatment},
  year={2013}
}
BACKGROUND Pharmacokinetic and safety data on stimulants in older adults are limited. The objective of this study was to characterize the pharmacokinetics of lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, in older adults. METHODS In this two-period crossover trial, healthy adults (n = 47) stratified by age (55-64, 65-74, and ≥ 75 years) and gender received randomized, double-blind, single doses of LDX 50 mg or placebo. Baseline creatinine clearance, d-amphetamine and intact LDX… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Aging and kidney disease

  • BM Brenner, SA Levine
  • Brenner and Rector ’ s The Kidney
  • 2010

Similar Papers

Loading similar papers…